Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing validity.
CATEGORIES News Events Publications ARCHIVE Chris Ehrlich of Locust Walk to speak at Dartmouth Entrepreneurs Forum On September 6, 2019, Chris
I recently returned from a month in Europe as part of our effort to expand Locust Walk’s European practice. It was an amazing trip meeting great people and learning valuable lessons.
Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including,
CATEGORIES Advisory boards Asian Capabilities Capital Markets Capital Raising Commercial Assessment Events Finance Locust Walk Institute Market Trends Multitrack Process
CATEGORIES News Events Publications ARCHIVE Geoff Meyerson to Moderate Panel at Crush Life Sciences Board Meeting The Crush Life Sciences
Special Report on the U.S. Biopharmaceuticals Industry 2019
Selected quotes from the interview with Geoff Meyerson, CEO and Co-Founder of Locust Walk
Clear, data-based financial assumptions are essential to driving a successful deal process. In a previous post, The Value of a Commercial Assessment in Supporting a Transaction
Pursuing multiple deal options in parallel, known as a multi-track process, can create competitive tension that will enable a company to obtain the most value out of the deal
It is that time of year again when the orthopedics community comes together to reflect on the recent American Academy of Orthopedic Surgeons (AAOS) meeting which took place in Las Vegas and finished late last week.